Synthesis of fluorine-18-labeled Ciprofloxacin for PET studies in humans

被引:28
作者
Langer, O [1 ]
Mitterhauser, M
Brunner, M
Zeitlinger, M
Wadsak, W
Mayer, BX
Kletter, K
Müller, M
机构
[1] Univ Vienna, Sch Med, Div Clin Pharmacokinet, Dept Clin Pharmacol, Vienna, Austria
[2] Univ Vienna, Sch Med, Dept Nucl Med, Vienna, Austria
[3] Gen Hosp Vienna, Hosp Pharm, Vienna, Austria
[4] Univ Vienna, Inst Pharmaceut Technol, Vienna, Austria
关键词
fluoroquinolones; F-18]Ciprofloxacin; positron emission tomography; pharmacokinetics; humans; in vivo;
D O I
10.1016/S0969-8051(02)00444-4
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Ciprofloxacin (1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-quinoline-3-carboxylic acid), a widely-prescribed antibiotic, was labeled with fluorine-18 with the aim to perform positron emission tomography studies in humans for pharmacokinetic measurements. Due to a lack of chemical activation of ciprofloxacin for a direct nucleophilic exchange reaction a novel two-step synthetic approach, which employed an activated 6-fluoro-7-chloro substituted precursor molecule, was developed. The radiosynthesis yielded, starting from 52.5+/-11.3 GBq of [F-18]fluoride. 1.3+/-0.6 GBq (n=13) [F-18]ciprofloxacin ready for intravenous administration in about 130 min synthesis time. A series of analytical tests was performed in order to prove the identity of the radiolabeled compound and its suitability for human applications. (C) 2003 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:285 / 291
页数:7
相关论文
共 22 条
[1]  
[Anonymous], M100S111 NCCLS
[2]   F-18-labeling and biodistribution of the novel fluoro-quinolone antimicrobial agent, trovafloxacin (CP 99,219) [J].
Babich, JW ;
Rubin, RH ;
Graham, WA ;
Wilkinson, RA ;
Vincent, J ;
Fischman, AJ .
NUCLEAR MEDICINE AND BIOLOGY, 1996, 23 (08) :995-998
[3]   Distribution and antimicrobial activity of ciprofloxacin in human soft tissues [J].
Brunner, M ;
Hollenstein, U ;
Delacher, S ;
Jäger, D ;
Schmid, R ;
Lackner, E ;
Georgopoulos, A ;
Eichler, HG ;
Müller, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) :1307-1309
[4]   A combined in vivo pharmacokinetic-in vitro pharmacodynamic approach to simulate target site pharmacodynamics of antibiotics in humans [J].
Delacher, S ;
Derendorf, H ;
Hollenstein, U ;
Brunner, M ;
Joukhadar, C ;
Hofmann, S ;
Georgopoulos, A ;
Eichler, HG ;
Müller, M .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (05) :733-739
[5]   Mechanism of fluoroquinolone action [J].
Drlica, K .
CURRENT OPINION IN MICROBIOLOGY, 1999, 2 (05) :504-508
[6]  
Eichler HG, 1998, CLIN PHARMACOKINET, V34, P95
[7]   Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography [J].
Fischman, AJ ;
Babich, JW ;
Bonab, AA ;
Alpert, NM ;
Vincent, J ;
Callahan, RJ ;
Correia, JA ;
Rubin, RH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) :2048-2054
[8]   The role of positron emission tomography in pharmacokinetic analysis [J].
Fischman, AJ ;
Alpert, NM ;
Babich, JW ;
Rubin, RH .
DRUG METABOLISM REVIEWS, 1997, 29 (04) :923-956
[9]   Pharmacokinetic imaging - A noninvasive method for determining drug distribution and action [J].
Fischman, AJ ;
Alpert, NM ;
Rubin, RH .
CLINICAL PHARMACOKINETICS, 2002, 41 (08) :581-602
[10]  
HERMECZ I, 1988, Patent No. 8807993